and Human Services (HHS)
EXPIRED
STRATEGIES FOR GERM-LINE MODIFICATION IN THE RAT
Release Date: April 3, 2001
PA NUMBER: PAR-01-077
National Center for Research Resources
National Cancer Institute
National Heart, Lung, and Blood Institute
National Institute of Child Health and Human Development
National Institute of Neurological Disorders and Stroke
National Institute on Aging
National Institute on Drug Abuse
Letter of Intent Receipt Dates: September 1, 2001; September 1, 2002 and
September 1, 2003.
Application Receipt Dates: October 1, 2001; October 1, 2002 and
October 1, 2003.
THIS PA USES "MODULAR GRANT" AND "JUST-IN-TIME" CONCEPTS. THIS PAR INCLUDES
DETAILED MODIFICATIONS TO STANDARD APPLICATION INSTRUCTIONS THAT MUST BE USED
WHEN PREPARING AN APPLICATION IN RESPONSE TO THIS PAR.
PURPOSE
The National Center for Research Resources, National Cancer Institute,
National Heart, Lung and Blood Institute, National Institute of Child Health
and Human Development, National Institute of Neurological Disorders and
Stroke, National Institute on Aging, and National Institute on Drug Abuse,
invite applications for the purpose of establishing methods for the efficient
production of rat models that contain germ-line mutations that will
facilitate the transfer of biological concepts to human health problems.
Development of rat embryonic stem cell (ESC) technology by modification of
current techniques or development of new approaches will meet the needs of
researchers using the rat to study human health and disease. This initiative
is designed for rat models only and should not include human subjects or
tissues.
HEALTHY PEOPLE 2010
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2010," a PHS-
led national activity for setting priority areas. This Program Announcement
(PAR), STRATEGIES FOR GERM-LINE MODIFICATION IN THE RAT, is related to
several priority areas. Potential applicants may obtain a copy of "Healthy
People 2010" at http://www.health.gov/healthypeople/.
ELIGIBILITY REQUIREMENTS
Applications may be submitted by domestic and foreign, for-profit and non-
profit organizations, public and private, such as universities, colleges,
hospitals, laboratories, units of State and local governments, and eligible
agencies of the Federal government. Racial/ethnic minority individuals,
women, and persons with disabilities are encouraged to apply as principal
investigators.
MECHANISM OF SUPPORT
This PAR will use the National Institutes of Health (NIH) Research Project
Grant (R01) mechanism. Responsibility for the planning, direction, and
execution of the proposed project will be solely that of the applicant. The
total project period for an application submitted in response to this PAR may
not exceed five years.
For all competing R01 applications requesting up to $250,000 per year in
direct costs, specific application instructions have been modified to reflect
MODULAR GRANT and JUST-IN-TIME streamlining efforts being examined by
NIH. Complete and detailed instructions and information on Modular Grant
applications can be found at
http://grants.nih.gov/grants/funding/modular/modular.htm. Applications that
request more than $250,000 in any year must use the standard PHS 398 (rev.
4/98) application instructions.
RESEARCH OBJECTIVES
The ability to engineer custom mutants, transgenic, and knockout animals has
opened up a new era of scientific discovery and now allows testing of
hypotheses previously limited by the available animal models. Recent
extensions of the knockout technology using homologous recombination have
included tissue-specific knockouts and knock-in mutations to allow generation
of custom made mutations. A complete functional analysis of genes requires
both gain of function and loss of function mutations. The ability to produce
these mutations for genes of choice is proving to be extremely important to
exploiting gene discovery by creating animal models of human disease. Gain
of function mutations through transgenic mice and rats are now routine.
However, creation of loss of function mutations by knock-out technology is
only routine in the mouse. Hence, germ-line modification in the rat is
critically important to assigning function to specific genes and to
identifying gene alterations responsible for specific phenotypes. The
analysis of phenotypes from gain of function and loss of function has been
the most direct and useful way to connect specific genes to phenotypes
relevant to human disease. The accessibility to technologies for modifying
the rat germ line is limited and needs to be extended.
Rats are widely used as a scientific model of human physiology because of
several unique characteristics including size, extensive phenotype data, and
importantly, relevance to many aspects of human biology. Size alone makes a
strong argument for continuing to use the laboratory rat, particularly for
procedures involving manipulations such as intravenous cannulation, nerve
recordings, collection of tissue from small structures, and serial blood
sampling. There is an impressive array of well characterized rat strains
utilized for the study of public health concerns. For example, there are
nine inbred strains used in studies of arterial pressure regulation and
hypertension alone. Two of the strains, Dahl’s and Brown Norway, have been
employed successfully in multiple cosegregation analysis leading to the
identification of more than 30 regions on 16 chromosomes that affect likely
determinants of blood pressure. Because of the extensive genomic tools
available for the rat and the high degree of conserved linkage between the
rat and humans, these chromosomal regions were quickly translated to both
known human chromosomal regions that affect blood pressure and to gene
discovery. Rats provide very important and useful models in the area of
neurobehavior and addiction. This is because of the extensive extant data on
neuropharmacology and neuroanatomy in the rat, because the size of the brain
structures allows a higher degree of anatomical resolution in molecular
studies than in other common laboratory animals, and because the rat is
particularly well suited to reproducible training in drug self-
administration. In learning studies such as mazes, it is now apparent that
the rat learns in a manner much more like humans than do some other mammals.
The rat is the most important model of human arthritis and related autoimmune
diseases, with more than 200 inbred, congenic and mutant strains with
important variations in disease related variables. Gender related variables
and gender differences in arthritis in the rat are more similar to humans
than are those of other mammals. There are extensive toxicological and
pharmacological data in the rat with high relevance to the human condition.
Considering the significant use of rat models in cardiovascular biology,
renal and pulmonary disease, reproduction, neurobiology, immunology, cancer,
diabetes, arthritis and autoimmune disease, and endocrinology, to name a few,
it is imperative that the ability to manipulate the rat genome be developed.
The application of genetic engineering technologies to the rat is an
important step for understanding the pathology underlying many human
diseases. There are many examples that illustrate the power and importance
of targeted, germ-line modification. One example is the series of studies
performed a few years ago with calcium/calmodulin kinase II gene knockout
mice. These mice were used to demonstrate the role of this gene in neural
transmission, synaptic plasticity, learning, and behavior. Studies on the
role of specific neurotransmitter systems in learning and memory have in the
past relied on the use of inhibitors and agonists to dissect the pathways.
As a second example, the isolation of human renin genes led to the production
of renin transgenic rats. These animals provided important insight into the
quantitative traits that the gene product regulates. However, the studies
had to be done in the presence of the endogenous rat renin genes. Complete
functional analysis of the human renin genetic system will require knocking
out the renin system one element at a time and inserting the human genes.
The ability to generate specific genetic modifications in rats would
contribute rapidly to our understanding of development, physiology and
pathobiology.
Many genetic engineering techniques have proven to be equally efficient in a
variety of mammalian species, including the rat. However, in one very
important area, ESCs, it has not been possible to adapt the mouse technology
to the rat. Cells are cultured from the inner cell mass of mouse blastocysts
and those cells are propagated under conditions that maintain them in an
undifferentiated pluripotent state. The cells can be manipulated
genetically, typically by homologous recombination, and selected for
heterozygous loss of function mutations. When the cells are injected into
normal preimplantation embryos and transferred to surrogate mothers, live
offspring bearing the mutation can be obtained. These are mated to
homozygosity for study. The success of this procedure depends on the ability
to obtain germ-line transmission of the modified genome. Unfortunately, it
appears likely that the mouse is the exception rather than the rule regarding
the ability to culture totipotent ESCs, as germ-line transmission has not yet
been reported with ESCs from any species other than mouse and chicken.
Several rat ESC lines have been developed, but these have not yet proven to
be pluripotent.
Nuclear transfer (NT) technology has resulted in live cloning in several
species, including mice, sheep, cattle and monkeys. These successes
demonstrate the wide species-applicability of nuclear transfer technology,
unlike the ESC technology. Moreover, genetically modified cells have been
successfully used as nuclear donors. Therefore, cells that can be used to
develop live born clones of the rat could be used in conjunction with
homologous recombination or other mutational strategies to develop cells with
desired mutations necessary for functional analysis of critical genes. These
cells could then be used for nuclear donors in NT and thereby directly
generate mutant animals. NT could provide a flexible means for modifying the
rat genome in that there is the potential to use many different kinds of
cells for the genetic modifications, including cells from adult tissues.
This flexibility also makes cryopreservation of the modified genome much
easier, as most cultured cells are easier to store than embryos. NT can be
used in principle to enhance repository services as well, since a variety of
cells could be used to preserve or transport rare strains. The addition of a
variety of standard approaches, like cloning, can be used to further enhance
the availability of rat animal models.
Since the development of pluripotent ESCs appears to be limited to certain
species, technological advancements for producing gene knockouts in the rat
should be emphasized. The development of genetic modification technology
will allow investigators using the rat model to capitalize on related
initiatives in progress or recently completed, including the Rat Genome
Project, the Rat EST Project, and the Rat Genome Sequencing Project.
Some illustrative examples of research topics that could be addressed under
this program announcement are:
o Strategies for culturing pluripotent rat ESCs to allow genetic
manipulation and to create rats with germ-line transmission of genetic
modifications.
o Development of alternative technologies to create null mutations or gene
replacement in the rat.
o Development of cost-effective NT procedures in the rat.
o Studies that demonstrate mutation transfer to rat stem cells or other
cells for transfer into embryos or germ cells.
o Methods for targeting engineered introns into rat chromosomal DNA to
support the study of gene function.
SHARING OF MATERIALS GENERATED UNDER THIS PA
To address the joint interest of the government in the availability of, and
access to, the results of publicly funded research, NIH requires applicants
who respond to this PAR to propose detailed plans for sharing the research
resources generated through the grant. It is expected that the resources to
be shared will include, among others, cell lines, mutant animals, germplasm,
nucleic acid sequences, and novel reagents and techniques useful for meeting
the goals of this PAR. These various research resources will be of great
value to the broader research community, beyond the laboratories that create
them. It is preferable that resources generated under this PAR should be
placed in common, public repositories and databases that are widely
accessible to investigators in the scientific community.
The required resource sharing plan will include a description of the
mechanisms proposed for wide distribution of resources with investigators in
the scientific community, as described in more detail, below. The reviewers
will provide an administrative comment evaluating the adequacy and
feasibility of the resource sharing plan. This comment will not affect the
priority score of the proposal. NIH staff will consider the adequacy of the
plan in determining whether to recommend an application for award. The
sharing plan as approved, after negotiation with the applicant as necessary,
will become a condition of the grant award. Progress reports must contain
information on sharing of resources as they are developed. For more detailed
guidance on NIH policies on resource sharing, applicants are referred to
Principles and Guidelines for Recipients of NIH Research Grants and
Contracts on Obtaining and Disseminating Biomedical Research Resources,
http://www.ott.nih.gov/policy/rt_guide_final.html.
INTELLECTUAL PROPERTY
Applicants should refer to the NIH Principles and Guidelines for Recipients
of NIH Research Grants and Contracts on Obtaining and Disseminating
Biomedical Research Resources, as referenced above. When a recipient’s
research is funded by NIH, the activity is subject to various laws and
regulations, including the Bayh-Dole Act (35 U.S.C. 200, et seq). The Bayh-
Dole Act is implemented through Department of Commerce regulations 37 CFR
401. These regulations define terms, parties, responsibilities, prescribe
the order of disposition of rights, prescribe a chronology of reporting
requirements, and delineate the basis for and extent of government actions to
retain rights. In accordance with statute, these rights should be used to
promote free competition and enterprise without unduly encumbering future
research and discovery. The patent rights clauses are found at 37 CFR Part
401.14 and are accessible from the Interagency Edison web page,
http://www.iedison.gov/.
LETTER OF INTENT
Prospective applicants are strongly encouraged to submit, by the dates listed
on page one of this program announcement, a letter of intent that includes a
descriptive title of the proposed research, the name, address, and telephone
number of the Principal Investigator, the identities of other key personnel
and participating institutions, and the number and title of the PAR in
response to which the application will be submitted. Although a letter of
intent is not required, is not binding, and does not enter into the review of
a subsequent application, the information that it contains allows NIH staff
to estimate the potential review workload and to plan the review.
The letter of intent is to be sent to:
John D. Harding, Ph.D.
Division of Comparative Medicine
National Center for Research Resources
6705 Rockledge Drive, Suite 6050, MSC 7965
Bethesda, MD 20892-7965
(Bethesda MD 20817 for express service)
Telephone: (301) 435-0776
FAX: (301) 480-3819
Email: [email protected]
URLS IN NIH GRANT APPLICATIONS OR APPENDICES
All applications and proposals for NIH funding must be self-contained within
specified page limitations. Unless otherwise specified in an NIH
solicitation, Internet addresses (URLs) should not be used to provide
information necessary to the review because reviewers are under no obligation
to view the Internet sites. Reviewers are cautioned that their anonymity may
be compromised when they directly access an Internet site.
APPLICATION PROCEDURES
Applicants are strongly encouraged to contact the program staff listed under
INQUIRIES with any questions regarding their proposed project and the goals
of this PAR. Applications are to be submitted on the grant application form
PHS 398 (rev.4/98 or latest revision) and will be accepted on the dates
listed on page one of this PAR. Application kits are available at most
institutional offices of sponsored research and from the Division of
Extramural Outreach and Information Resources, National Institutes of Health,
6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone (301) 710-0267, Email: [email protected]. Applications are also available on the
World Wide Web at: http://grants.nih.gov/grants/forms.htm.
Applicants planning to submit an investigator-initiated new (type 1),
competing continuation (type 2), competing supplement, or any amended/revised
version of the preceding grant application types requesting $500,000 or more
in direct costs for any year are advised that he or she must contact the
Institute or Center (IC) program staff before submitting the application,
i.e., as plans for the study are being developed. Furthermore, the applicant
must obtain agreement from the IC staff that the IC will accept the
application for consideration for award. Finally, the applicant must
identify, in a cover letter sent with the application, the staff member and
IC who agreed to accept assignment of the application.
This policy requires an applicant to obtain agreement for acceptance of both
any such application and any such subsequent amendment. Refer to the NIH
Guide for Grants and Contracts, March 20, 1998 at
http://grants.nih.gov/grants/guide/notice-files/not98-030.html.
ADDITIONAL INSTRUCTIONS: SHARING OF MATERIALS
In addition to the instructions contained in the PHS 398, an application must
include a section describing plans for sharing of materials. This section
can not exceed three pages in length and should directly follow the Research
Design and Methods section of the research plan. The text of the section on
Sharing of Materials will not be considered part of the 25 page limit of the
research plan.
The section on Sharing of Materials should include the following information:
1) A listing of the research resources that the applicant expects to derive.
Both tangible items such as cell lines, mutant animals, germplasm and
reagents, as well as non-tangible items such as techniques and nucleic acid
sequences, should be considered as research resources that should be shared
with other investigators. 2) A description of the mechanisms proposed for
wide distribution of resources with investigators in the scientific
community, and 3) a timetable for distribution of the resources. As
discussed above, the reviewers will evaluate this section and their comments
will be incorporated into an Administrative Note in the Summary Statement
that will be used by NIH Program personnel to help make funding decisions.
Information in this section will not be used by reviewers to determine the
priority score for the application.
SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS
The modular grant concept establishes specific modules in which direct costs
may be requested as well as a maximum level for requested budgets. Only
limited budgetary information is required under this approach. The just-in-
time concept allows applicants to submit certain information only when there
is a possibility for an award. It is anticipated that these changes will
reduce the administrative burden for the applicants, reviewers and Institute
staff. The research grant application form PHS 398 (rev. 4/98) is to be used
in applying for these grants, with the modifications noted below.
BUDGET INSTRUCTIONS
Modular Grant applications will request direct costs in $25,000 modules, up
to a total direct cost request of $250,000 per year. (Applications that
request more than $250,000 direct costs in any year must follow the
traditional PHS 398 application instructions). The total direct costs must
be requested in accordance with the program guidelines and the modifications
made to the standard PHS 398 application instructions described below:
PHS 398:
o FACE PAGE. Items 7a and 7b should be completed, indicating Direct Costs
(in $25,000 increments up to a maximum of $250,000) and total Costs [Modular
Total Direct plus Facilities and Administrative (F&A) costs] for the initial
budget period. Items 8a and 8b should be completed, indicating the Direct
and Total Costs for the entire proposed period of support.
o DETAILED BUDGET FOR THE INITIAL BUDGET PERIOD. Do not complete Form Page
4 of the PHS 398. It is not required for modular grant applications and will
not be accepted with the application.
o BUDGET FOR THE ENTIRE PROPOSED PERIOD OF SUPPORT. Do not complete the
categorical budget table on Form Page 5 of the PHS 398. It is not required
for modular grant applications and will not be accepted with the application.
o NARRATIVE BUDGET JUSTIFICATION. Prepare a Modular Grant Budget Narrative
page. (See http://grants.nih.gov/grants/funding/modular/modular.htm for
sample pages.) At the top of the page, enter the total direct costs
requested for each year. This is not a Form page.
o Under Personnel, list all project personnel, including their names,
percent of effort, and roles on the project. No individual salary
information should be provided. However, the applicant should use the NIH
appropriation language salary cap and the NIH policy for graduate student
compensation in developing the budget request.
o For Consortium/Contractual costs, provide an estimate of total costs
(direct plus F&A costs) for each year, each rounded to the nearest $1,000.
List the individuals/organizations with whom consortium or contractual
arrangements have been made, the percent effort of all personnel, and the
role on the project. Indicate whether the collaborating institution is
foreign or domestic. The total cost for a consortium/contractual arrangement
is included in the overall requested modular direct cost amount. Include the
Letter of Intent to establish a consortium.
Provide an additional narrative budget justification for any variation in the
number of modules requested.
o BIOGRAPHICAL SKETCH. The Biographical Sketch provides information used by
reviewers in the assessment of each individual's qualifications for a
specific role in the proposed project, as well as to evaluate the overall
qualifications of the research team. A biographical sketch is required for
all key personnel, following the instructions below. No more than three
pages may be used for each person. A sample biographical sketch may be
viewed at: http://grants.nih.gov/grants/funding/modular/modular.htm.
- Complete the educational block at the top of the form page.
- List position(s) and any honors.
- Provide information, including overall goals and responsibilities, on
research projects ongoing or completed during the last three years.
- List selected peer-reviewed publications, with full citations.
o CHECKLIST. This page should be completed and submitted with the
application. If the F&A rate agreement has been established, indicate the
type of agreement and the date. All appropriate exclusions must be applied
in the calculation of the F&A costs for the initial budget period and all
future budget years.
o The applicant should provide the name and phone number of the individual
to contact concerning fiscal and administrative issues if additional
information is necessary following the initial review.
The title and number of the program announcement must be typed on line 2 of
the face page of the application form and the YES box must be marked.
SUBMITTING THE APPLICATION.
Submit a signed, typewritten original of the application, including the
Checklist, and four signed photocopies in one package to:
CENTER FOR SCIENTIFIC REVIEW
NATIONAL INSTITUTES OF HEALTH
6701 ROCKLEDGE DRIVE, ROOM 1040, MSC 7710
BETHESDA, MD 20892-7710
BETHESDA, MD 20817 (for express/courier service)
At the time of submission, one additional copy of the application must be
sent to:
John D. Harding, Ph.D.
Division of Comparative Medicine
National Center for Research Resources
6705 Rockledge Drive, Suite 6050, MSC 7965
Bethesda, MD 20892-7965
(Bethesda MD 20817 for express service)
Telephone: (301) 435-0776
FAX: (301) 480-3819
Email: [email protected]
REVIEW CONSIDERATIONS
Applications will be assigned on the basis of established PHS referral
guidelines and will be reviewed for completeness by the Center for Scientific
Review (CSR). Applications will be evaluated for scientific and technical
merit by an appropriate scientific review group convened by the Office of
Review, NCRR, in accordance with standard NIH peer review procedures. As
part of the initial merit review, all applications will receive a written
critique and undergo a process in which only those applications deemed to
have the highest scientific merit, generally the top half of applications
under review, will be discussed, assigned a priority score, and receive a
second level review by the appropriate national advisory council.
Review Criteria
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health. In
the written comments reviewers will be asked to discuss the aspects of the
application listed below, in order to judge the likelihood that the proposed
research will have a substantial impact on the pursuit of these goals. Each
of these criteria will be addressed and considered in assigning the overall
score, weighting them as appropriate for each application. Note that the
application does not need to be strong in all categories to be judged likely
to have major scientific impact and thus deserve a high priority score. For
example, an investigator may propose to carry out important work that by its
nature is not innovative but is essential to move a field forward.
Furthermore, because of the subject matter of this PA, some applications may
have more of an applied component than does a typical investigator-initiated
R01 application. This is appropriate as long as the applied component
addresses the purposes of the PA.
The specific review criteria are:
1) Significance: Does this study address an important problem? If the aims
of the application are achieved, how will scientific knowledge be advanced?
What will be the effect of these studies on the concepts or methods that
drive this field?
2) Approach: Are the conceptual framework, design, methods, and analyses
adequately developed, well-integrated, and appropriate to the aims of the
project? Does the applicant acknowledge potential problem areas and consider
alternative tactics?
3) Innovation: Does the project employ novel concepts, approaches or
methods? Are the aims original and innovative? Does the project challenge
existing paradigms or develop new methodologies or technologies?
4) Investigator: Is the investigator appropriately trained and well suited
to carry out this work? Is the work proposed appropriate to the experience
level of the principal investigator and other researchers (if any)?
5) Environment: Does the scientific environment in which the work will be
done contribute to the probability of success? Do the proposed experiments
take advantage of unique features of the scientific environment or employ
useful collaborative arrangements? Is there evidence of institutional
support?
In addition to the above criteria, in accordance with NIH policy, all
applications will also be reviewed with respect to the following:
o The reasonableness of the proposed budget and duration in relation to the
proposed research.
o The adequacy of the proposed protection for animals or the environment, to
the extent they may be adversely affected by the project proposed in the
application.
o The appropriateness of the plans for sharing of research resources.
SCHEDULE
Letter of Intent Receipt Date: September 1, 2001; September 1, 2002
or September 1, 2003.
Application Receipt Date: October 1, 2001, October 1, 2002,
or October 1, 2003.
Peer Review Date: February - March of each respective year.
Council Review: May June of each respective year.
Earliest Anticipated Start Date: July of each respective year.
AWARD CRITERIA
Applications will compete for available funds with all other recommended
applications assigned to the Institute. The following will be considered in
making funding decisions: Quality of the proposed project as determined by
peer review, availability of funds, and program priority.
INQUIRIES
Inquiries are encouraged. The opportunity to clarify any issues or questions
from potential applicants is welcome.
Direct inquiries regarding programmatic issues to:
John D. Harding, Ph.D.
Division of Comparative Medicine
National Center for Research Resources
6705 Rockledge Drive, Suite 6050, MSC 7965
Bethesda, MD 20892-7965
Telephone: (301) 435-0776
FAX: (301) 480-3819
E-mail: [email protected]
Judy Mietz, Ph.D.
Division of Cancer Biology
National Cancer Institute
6130 Executive Boulevard, EPN 5032
Bethesda, MD 20892
Telephone: (301) 496-7028
FAX: (301) 402-1037
Email: [email protected]
Martha S. Lundberg, Ph.D.
Division of Heart and Vascular Diseases
National Heart, Lung and Blood Institute
6701 Rockledge Drive
Rockledge II, Room 9146
Bethesda, MD 20892-7940
Telephone: (301) 435-0513
FAX: (301) 480-1335
E-mail: [email protected]
Mary Lou Oster-Granite, Ph. D.
Mental Retardation and Developmental Disabilities Branch
National Institute of Child Health and Human Development
6100 Executive Boulevard, Room 4B-09, MSC 7510
Bethesda, MD 20892-7510
Telephone: (301) 435-6866
FAX: (301) 496-3791
Email: [email protected]
Arlene Y. Chiu, Ph.D.
Repair and Plasticity Program
National Institute of Neurological Disorders and Stroke
Neuroscience Center, Room 2206
6001 Executive Boulevard
Bethesda, MD 20892
Telephone: (301) 496-1447
FAX: (301) 480-1080
Email: [email protected]
Nancy L. Nadon, Ph.D.
Biology of Aging Program
National Institute on Aging
7201 Wisconsin Avenue, GW 2C231
Bethesda, MD 20892
Telephone: (301) 496-6402
FAX: (301) 402-0010
E-mail: [email protected]
Jonathan D. Pollock, Ph.D.
Genetics and Molecular Neurobiology Branch
Division of Neuroscience and Behavioral Research
National Institute on Drug Abuse
6001 Executive Boulevard
Rockville, MD 20892
Telephone: (301) 435-1309
FAX: (301) 594-6043
E-mail: [email protected]
Direct inquiries regarding fiscal matters to:
Ms. Irene Grissom
Office of Grants Management
National Center for Research Resources
6705 Rockledge Drive, Room 6086
Bethesda, MD 20892
Telephone: (301) 435-0844
FAX: (301) 480-3777
Email: [email protected]
Ms. Crystal Wolfrey
Grants Administration Branch
National Cancer Institute
6120 Executive Boulevard, Room 243
Bethesda, MD 20892
Telephone: (301) 496-8634
FAX: (301) 496-8601
Email: [email protected]
David Reiter
Division of Extramural Affairs
National Heart, Lung and Blood Institute
6701 Rockledge Drive
Rockledge II, Room 7142
Bethesda, MD 20892-7940
Telephone: (301) 435-0177
FAX: (301) 480-3310
E-mail: [email protected]
Mr. Douglas Shawver
Grants Management Branch
National Institute of Child Health and Human Development
6100 Executive Boulevard, Room 8A-17, MSC 7510
Bethesda, MD 20892-7510
Telephone: (301) 435-6999
FAX: (301) 420-0915
E-mail: [email protected]
Ms. Rita Sisco
Grants Management Branch, DER
National Institute of Neurological Disorders and Stroke
Neuroscience Center, Room 3290, MSC 9537
6001 Executive Boulevard
Bethesda, MD 20892
Telephone: (301) 496-7488
FAX: (301) 402-0219
Email: [email protected]
Ms. Linda Whipp
Grants and Contracts Management Office
National Institute on Aging
7201 Wisconsin Avenue, GW 2N212
Bethesda, MD 20892
Telephone: (301) 496-1472
FAX: (301) 402-3672
E-mail: [email protected]
Gary Fleming, J.D., M.A.
Grants Management Branch
Office of Planning and Resource Management
National Institute on Drug Abuse
6001 Executive Boulevard, Room 3131, MSC 9541
Bethesda, MD 20892-9541
Telephone: (301) 443-6710
FAX: (301) 594-6847
E-mail: [email protected]
AUTHORITY AND REGULATIONS
This program is described in the Catalog of Federal Domestic Assistance No.
93.306, 93.396, 93.837, 93.865, 93.853, 93.866, and 93.279. Awards are made
under authorization of Sections 301 and 405 of the Public Health Service Act
as amended (42 USC 241 and 284) and administered under PHS grants policies
and Federal Regulations 42 CFR 52 and 45 CFR Part 74 and 92. This program is
not subject to the intergovernmental review requirements of Executive Order
12372 or Health Systems Agency review.
The PHS strongly encourages all grant and contract recipients to provide a
smoke-free workplace and promote the non-use of all tobacco products. In
addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking
in certain facilities (or in some cases, and portion of a facility) in which
regular or routine education, library, day care, health care or early
childhood development services are provided to children. This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||